WEBULL
WebtradeDownload

RHÖN-KLINIKUM (XTRA:RHK) Could Be 13% Above Fair Value On Earnings And 2026 Guidance

Simply Wall St · 1d ago

RHÖN-KLINIKUM (XTRA:RHK) stock action is drawing attention after the company issued 2026 revenue guidance of about €1.7b, plus or minus 5%, alongside its latest quarterly and half year earnings report.

See our latest analysis for RHÖN-KLINIKUM.

That guidance and the stronger second quarter and half year earnings land against a share price that has risen 17.2% over the past week and 19.1% over the past 90 days, while RHÖN-KLINIKUM’s 1 year total shareholder return of 33.7% contrasts with a broadly flat 5 year total shareholder return.

If this earnings update has you looking beyond hospitals, it could be a good moment to widen your search with 133 healthcare AI stocks

RHÖN-KLINIKUM now pairs recent earnings momentum and fresh 2026 guidance with a share price that has already moved sharply higher. Does that add up to a well priced hospital operator today, or has the stock run ahead of itself?

Price-to-Earnings of 23.9x: Is it justified?

RHÖN-KLINIKUM currently trades on a P/E of 23.9x, which sits above both its peer group and the broader European Healthcare average, even after the recent share price move to €15.

The P/E ratio compares the company’s share price to its earnings per share. A higher multiple usually reflects the market paying more today for each euro of current earnings. For a hospital operator like RHÖN-KLINIKUM that reports relatively modest net profit margins of 2.1%, this kind of premium often implies the market is putting a value on the quality and stability of earnings, as well as expectations for future profit growth.

Here the comparison points are clear. The company’s 23.9x P/E sits above the peer average of 17.7x and also above the European Healthcare sector average of 20.3x. It is also higher than the estimated fair P/E of 19.3x that the SWS model suggests the market could converge toward over time. That combination points to RHÖN-KLINIKUM trading at a richer multiple than both its peers and its own fair ratio benchmark.

Explore the SWS fair ratio for RHÖN-KLINIKUM

Result: Price-to-Earnings of 23.9x (OVERVALUED)

However, RHÖN-KLINIKUM’s richer P/E and the strong recent share price run could face pressure if earnings momentum softens or regulatory costs weigh on margins.

Find out about the key risks to this RHÖN-KLINIKUM narrative.

Another view on RHÖN-KLINIKUM’s valuation

The SWS DCF model points to an estimated future cash flow value of about €13.24 per share for RHÖN-KLINIKUM, compared with the current price of €15. On this measure the stock screens as overvalued. If earnings or cash flows do not keep pace, it is unclear how patient the market will be.

Look into how the SWS DCF model arrives at its fair value.

RHK Discounted Cash Flow as at Aug 2026
RHK Discounted Cash Flow as at Aug 2026

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out RHÖN-KLINIKUM for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 252 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If the RHÖN-KLINIKUM story so far feels mixed, this is a good time to review the numbers yourself and decide where you stand. To see what investors are currently optimistic about, take a closer look at the 2 key rewards

Looking for more RHÖN-KLINIKUM sized opportunities?

Before moving on, take a moment to scan other ideas that could sit alongside RHÖN-KLINIKUM in a balanced portfolio, rather than backing a single story.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.